{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:23:26Z","timestamp":1794936206299,"version":"4.9.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI147598"],"award-info":[{"award-number":["R21 AI147598"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI176766"],"award-info":[{"award-number":["R21 AI176766"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI169851"],"award-info":[{"award-number":["R21 AI169851"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015629","name":"Jerome L Greene Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR069572"],"award-info":[{"award-number":["R01 AR069572"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.xcrm.2024.101569","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:31:37Z","timestamp":1715596297000},"page":"101569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE"],"prefix":"10.1016","volume":"5","author":[{"given":"Eduardo","family":"G\u00f3mez-Ba\u00f1uelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Darrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3415-0704","authenticated-orcid":false,"given":"Felipe","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101569_bib1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101569_bib3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping systemic lupus erythematosus heterogeneity at the single-cell level","volume":"21","author":"Nehar-Belaid","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib5","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101569_bib6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101569_bib8","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1016\/j.cell.2022.07.021","article-title":"Distinct transcriptome architectures underlying lupus establishment and exacerbation","volume":"185","author":"Nakano","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101569_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2263","article-title":"Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation","volume":"14","author":"Billi","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606489","article-title":"The Role of Structure in the Biology of Interferon Signaling","volume":"11","author":"Walter","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib14","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101569_bib15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1089\/jir.2011.0071","article-title":"Interferon Alpha as a Primary Pathogenic Factor in Human Lupus","volume":"31","author":"Niewold","year":"2011","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.xcrm.2024.101569_bib16","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet. Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101569_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101569_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib22","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/13543784.2020.1797677","article-title":"Type I interferon antagonists in clinical development for lupus","volume":"29","author":"Paredes","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.xcrm.2024.101569_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib25","article-title":"IFN-gamma, should not be ignored in SLE","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.xcrm.2024.101569_bib27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon-alpha","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2010.09.006","article-title":"The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types","volume":"53","author":"Moll","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.xcrm.2024.101569_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/107999099313901","article-title":"Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta","volume":"19","author":"Jabs","year":"1999","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.xcrm.2024.101569_bib31","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1186\/ar3363","article-title":"Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity","volume":"13","author":"Wu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.xcrm.2024.101569_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/RHU.0000000000000581","article-title":"Type III Interferons in Systemic Lupus Erythematosus: Association Between Interferon lambda3, Disease Activity, and Anti-Ro\/SSA Antibodies","volume":"23","author":"Amezcua-Guerra","year":"2017","journal-title":"J.\u00a0Clin. Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13075-018-1683-z","article-title":"Interferon-lambda3\/4 genetic variants and interferon-lambda3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese","volume":"20","author":"Chen","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.xcrm.2024.101569_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000170","article-title":"Interferon (IFN)-lambda is a potential mediator in lupus nephritis","volume":"3","author":"Zickert","year":"2016","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5114\/reum.2020.98434","article-title":"Impact of IL-34, IFN-alpha and IFN-lambda1 on activity of systemic lupus erythematosus in Egyptian patients","volume":"58","author":"Adel","year":"2020","journal-title":"Reumatologia"},{"key":"10.1016\/j.xcrm.2024.101569_bib36","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2024.101569_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2024.101569_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1126\/science.6176024","article-title":"Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon","volume":"216","author":"Preble","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101569_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun."},{"key":"10.1016\/j.xcrm.2024.101569_bib40","article-title":"The role of genetic variation near interferon-kappa in systemic lupus erythematosus","volume":"2010","author":"Harley","year":"2010","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101569_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000063","article-title":"BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year","volume":"2","author":"Zollars","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7862962","article-title":"Clinical Application of a Modular Genomics Technique in Systemic Lupus Erythematosus: Progress towards Precision Medicine","volume":"2016","author":"Zollars","year":"2016","journal-title":"Int. J. Genomics"},{"key":"10.1016\/j.xcrm.2024.101569_bib43","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.40653","article-title":"Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression","volume":"70","author":"Toro-Dom\u00ednguez","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib44","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/2041-210X.12797","article-title":"rptR: repeatability estimation and variance decomposition by generalized linear mixed-effects models","volume":"8","author":"Stoffel","year":"2017","journal-title":"Methods Ecol. Evol."},{"key":"10.1016\/j.xcrm.2024.101569_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163795","article-title":"Alternative exon usage in TRIM21 determines the antigenicity of Ro52\/TRIM21 in systemic lupus erythematosus","volume":"7","author":"Gomez-Ba\u00f1uelos","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2024.101569_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2024.101569_bib47","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum Interferon Levels in Patients with Systemic Lupus-Erythematosus","volume":"25","author":"Ytterberg","year":"1982","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2024.101569_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-alpha levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101569_bib50","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.xcrm.2024.101569_bib51","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2024.101569_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib53","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2024.101569_bib54","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41598-018-20203-9","article-title":"Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus","volume":"8","author":"Connelly","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101569_bib55","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","article-title":"Longitudinal expression of type I interferon responsive genes in systemic lupus\u00a0erythematosus","volume":"18","author":"Petri","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.xcrm.2024.101569_bib56","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.immuni.2012.01.011","article-title":"Constitutive type I interferon modulates homeostatic balance through tonic signaling","volume":"36","author":"Gough","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101569_bib57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/jaut.1998.0215","article-title":"Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells","volume":"11","author":"Cederblad","year":"1998","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.xcrm.2024.101569_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.688753","article-title":"Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus","volume":"12","author":"Enocsson","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib59","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/art.38038","article-title":"Interferon-alpha induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis","volume":"65","author":"Balboni","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2024.101569_bib60","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4049\/jimmunol.1800650","article-title":"Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus","volume":"202","author":"Tsoi","year":"2019","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101569_bib61","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-gamma Antibody, in Patients With Discoid Lupus Erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000226","article-title":"Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-gamma monoclonal antibody, in SLE subjects without or with lupus nephritis","volume":"4","author":"Boedigheimer","year":"2017","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib63","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2024.101569_bib64","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101569_bib65","first-page":"53","article-title":"Validity and reliability of lupus activity measures in the routine clinic setting","volume":"19","author":"Petri","year":"1992","journal-title":"J.\u00a0Rheumatol."},{"key":"10.1016\/j.xcrm.2024.101569_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nmeth.3252","article-title":"Orchestrating high-throughput genomic analysis with Bioconductor","volume":"12","author":"Huber","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101569_bib67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","article-title":"Dream: powerful differential expression analysis for repeated measures designs","volume":"37","author":"Hoffman","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101569_bib68","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101569_bib69","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101569_bib70","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2024.101569_bib71","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","article-title":"Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data","volume":"18","author":"Doncheva","year":"2019","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.xcrm.2024.101569_bib72","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1186\/1752-0509-8-S4-S11","article-title":"cytoHubba: identifying hub objects and sub-networks from complex interactome","volume":"8","author":"Chin","year":"2014","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.xcrm.2024.101569_bib73","first-page":"1","article-title":"brms: An R Package for Bayesian Multilevel Models Using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J.\u00a0Stat. Softw."},{"key":"10.1016\/j.xcrm.2024.101569_bib74","first-page":"1","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J.\u00a0Stat. Software"},{"key":"10.1016\/j.xcrm.2024.101569_bib75","series-title":"Modern Applied Statistics with S","author":"Venables","year":"2002"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T15:17:43Z","timestamp":1733757463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124002611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666379124002611"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101569","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.28.23294734","asserted-by":"object"}]},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101569"}}